Literature DB >> 27322875

A novel multivalent tuberculosis vaccine confers protection in a mouse model of tuberculosis.

Kristin L Griffiths1, Daniel O Villarreal2, David B Weiner2, Shabaana A Khader1.   

Abstract

Mycobacterium tuberculosis infects one third of the world's population. Due to variable efficacy of the Bacille Calmette Guerin (BCG) vaccine, development of novel TB vaccines remains a priority. Here, we demonstrate the protective efficacy of a novel multivalent DNA vaccine, which contains 15 synthetic antigens targeting the Mtb ESX secretion system.

Entities:  

Keywords:  DNA vaccine; Tuberculosis; vaccine

Mesh：

Substances：

Year:  2016        PMID： 27322875      PMCID： PMC5085007          DOI： 10.1080/21645515.2016.1197454

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  31 in total

1.  Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG.

Authors:  Daniel O Villarreal; Jewell Walters; Dominick J Laddy; Jian Yan; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  H-2 alleles contribute to antigen 85-specific interferon-gamma responses during Mycobacterium tuberculosis infection.

Authors:  Gillian L Beamer; Joshua Cyktor; Bridget Carruthers; Joanne Turner
Journal:  Cell Immunol       Date:  2011-06-12       Impact factor: 4.868

3.  Alarmin IL-33 elicits potent TB-specific cell-mediated responses.

Authors:  Daniel O Villarreal; Rebekah J Siefert; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model.

Authors:  Daniel O Villarreal; Nikolaos Svoronos; Megan C Wise; Devon J Shedlock; Matthew P Morrow; Jose R Conejo-Garcia; David B Weiner
Journal:  Vaccine       Date:  2015-04-14       Impact factor: 3.641

5.  Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system.

Authors:  Sarah A Stanley; Sridharan Raghavan; William W Hwang; Jeffery S Cox
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-13       Impact factor: 11.205

6.  Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12.

Authors:  Teruo Kaiga; Marimo Sato; Hide Kaneda; Yoichiro Iwakura; Tadatoshi Takayama; Hideaki Tahara
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

7.  Early secreted antigen ESAT-6 of Mycobacterium tuberculosis promotes protective T helper 17 cell responses in a toll-like receptor-2-dependent manner.

Authors:  Samit Chatterjee; Ved Prakash Dwivedi; Yogesh Singh; Imran Siddiqui; Pawan Sharma; Luc Van Kaer; Debprasad Chattopadhyay; Gobardhan Das
Journal:  PLoS Pathog       Date:  2011-11-10       Impact factor: 6.823

8.  Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis.

Authors:  S M Behar; C C Dascher; M J Grusby; C R Wang; M B Brenner
Journal:  J Exp Med       Date:  1999-06-21       Impact factor: 14.307

9.  Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis.

Authors:  R Gopal; J Rangel-Moreno; S Slight; Y Lin; H F Nawar; B A Fallert Junecko; T A Reinhart; J Kolls; T D Randall; T D Connell; S A Khader
Journal:  Mucosal Immunol       Date:  2013-01-09       Impact factor: 7.313

10.  Disseminated tuberculosis in interferon gamma gene-disrupted mice.

Authors:  A M Cooper; D K Dalton; T A Stewart; J P Griffin; D G Russell; I M Orme
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307
View more
  4 in total

Review 1.  Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections.

Authors:  Jan T Poolman
Journal:  NPJ Vaccines       Date:  2020-09-11       Impact factor: 7.344

2.  T cell transcription factor expression evolves over time in granulomas from Mycobacterium tuberculosis-infected cynomolgus macaques.

Authors:  Nicole L Grant; Pauline Maiello; Edwin Klein; Philana Ling Lin; H Jacob Borish; Jaime Tomko; L James Frye; Alexander G White; Denise E Kirschner; Joshua T Mattila; JoAnne L Flynn
Journal:  Cell Rep       Date:  2022-05-17       Impact factor: 9.995

3.  Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate Tuberculosis Subunit Vaccine.

Authors:  Elena Stylianou; Rachel Harrington-Kandt; Julia Beglov; Naomi Bull; Nawamin Pinpathomrat; Gwendolyn M Swarbrick; Deborah A Lewinsohn; David M Lewinsohn; Helen McShane
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441

4.  Development and Testing of a Spray-Dried Tuberculosis Vaccine Candidate in a Mouse Model.

Authors:  Mellissa Gomez; Mushtaq Ahmed; Shibali Das; Joseph McCollum; Leah Mellett; Rosemary Swanson; Ananya Gupta; Nicholas B Carrigy; Hui Wang; David Barona; Shital Bachchhav; Alana Gerhardt; Chris Press; Michelle C Archer; Hong Liang; Emilie Seydoux; Ryan M Kramer; Philip J Kuehl; Reinhard Vehring; Shabaana A Khader; Christopher B Fox
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.